# MOTS-c: Research Overview — Raw Wholesale Peptides > A literature summary of MOTS-c (mitochondrial-encoded peptide): AMPK activation mechanism, CK2 binding discovery, exercise-inducibility, mouse metabolic data, and why human trials are still absent. The only signaling peptide encoded inside the mitochondrial genome — activates AMPK via the folate cycle, enhances skeletal-muscle glucose uptake in mice, and has no completed human efficacy trials. ## The short version MOTS-c stands for **Mitochondrial Open Reading Frame of the 12S rRNA type-c**. It is a 16-amino-acid peptide encoded not in the nucleus but inside the mitochondrial 12S ribosomal RNA gene — making it the only signaling peptide known to originate from the mitochondrial genome. The sequence, MRWQEMGYIFYPRKLR, is highly conserved across mammals. Its best-understood mechanism runs through AMPK — the cellular energy sensor that muscles use to take up glucose and burn fuel more efficiently. MOTS-c gets there by inhibiting the folate cycle and de novo purine biosynthesis, which raises AICAR, which activates AMPK. A 2024 study further identified casein kinase 2 (CK2) as a direct molecular binding target, with tissue-specific effects on muscle glucose uptake and atrophy prevention [13]. In mice, exogenous MOTS-c enhanced physical performance and treadmill running capacity across young, middle-aged, and old animals [16]. The honest picture: all metabolic and performance efficacy data are from cell or animal studies. There are no completed human efficacy trials. MOTS-c is not approved for any use, is not a DEA-controlled substance, and is sold for laboratory research only. ## What it is MOTS-c is a 16-amino-acid peptide, sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). Unlike all other human peptide hormones and signaling molecules, whose genes sit in the nuclear genome, MOTS-c is made from mitochondrial genetic material — the small circular DNA that mitochondria carry independently of the nucleus. It is highly conserved across mammalian species. Natural variants exist: a pro-diabetogenic variant (m.1382A>C) and ancestry-dependent differences in exercise response suggest that MOTS-c effects are not uniform across all people. It circulates in human plasma and its levels respond to exercise and metabolic stress. There is no approved formulation or dosing — it is a research chemical sold for laboratory use. ## How it works Two interconnected pathways are best characterized. *Folate cycle inhibition leading to AMPK activation.* MOTS-c inhibits folate-cycle enzymes and de novo purine biosynthesis. This raises intracellular AICAR (an AMP-activated protein kinase activator), which activates AMPK — the master cellular energy sensor. In skeletal muscle, AMPK activation improves glucose uptake and insulin sensitivity. *CK2 direct binding (2024).* A 2024 study in cell-free systems identified casein kinase 2 (CK2) as a direct molecular target of MOTS-c. Tissue-specific CK2 modulation — activation in muscle, suppression in fat — was shown to underlie MOTS-c effects on muscle glucose uptake and prevention of skeletal muscle atrophy [13]. *Nuclear translocation.* Under metabolic stress, MOTS-c translocates from the mitochondrion to the nucleus and regulates nuclear gene expression in an AMPK-dependent manner, including antioxidant-response-element (ARE) genes via NRF2 — the first demonstrated retrograde mitochondria-to-nucleus signaling by a mitochondrially encoded peptide [17]. All of these mechanisms were characterized in cells or mice. Human pharmacokinetics, dose-response, and bioavailability have not been published in peer-reviewed literature. ## What the research shows *CK2 as direct target (2024).* In cell-free assays and in young, aged, high-fat-diet, and immobilized mice, MOTS-c directly bound and activated CK2. Tissue-specific CK2 modulation drove prevention of skeletal muscle atrophy and enhanced muscle glucose uptake [13]. *Exercise mimetic in aged mice.* Exercise induces endogenous MOTS-c expression in skeletal muscle and circulation. Exogenous MOTS-c significantly enhanced physical performance — treadmill running capacity (P=0.000002), grip strength, and gait — in aged (22-23.5 month) mice, and the effect was observed across young, middle-aged, and old animals. The paper positions MOTS-c as an exercise-mimetic regulator of healthspan [16]. *Nuclear stress signaling.* Under metabolic stress, MOTS-c translocated to the nucleus and regulated nuclear gene expression in an AMPK-dependent manner, including antioxidant and metabolic genes through NRF2 interaction — establishing the retrograde mitochondrial-to-nuclear signaling model [17]. *Comprehensive 2023 review.* A review synthesizing MOTS-c biology — MT-RNR1 encoding, AMPK/folate-cycle mechanism, nuclear translocation, exercise inducibility, and roles across metabolic, stress-adaptive, and aging pathways — serves as the modern orientation reference [15]. *Human biomarker association.* In a prospective multicenter cohort of 94 chronic hemodialysis patients (median 26.5-month follow-up), circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05); adding MOTS-c improved ROC AUC from 0.727 to 0.743. This is the strongest human clinical-association data for MOTS-c — an observational biomarker association, not an interventional outcome [14]. ## Reported effects, cautions & safety MOTS-c's controversy profile is dominated by the gap between mechanistic precision and clinical absence: **Cited cautions from the literature** - No human efficacy trials exist. Every claim about exogenous MOTS-c improving metabolism, performance, or aging comes from cell or animal studies. Human data are observational biomarker associations, not interventional outcomes [15]. - No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability, or dose-response; rodent doses (0.5-15 mg/kg/day) cannot be extrapolated to humans. - Research-chemical status. MOTS-c is not approved by the FDA for any use and is sold only for laboratory research; product purity, identity, and sterility vary by supplier and are not regulated as pharmaceuticals. - Anti-doping prohibition context. MOTS-c is treated as a prohibited peptide in elite sport, covered by anti-doping authorities such as USADA/WADA under hormone-and-metabolic-modulator categories; athletes face sanctions for use. - Ancestry and genotype interactions. A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses suggest effects are not uniform across populations. - Marketplace claims outpace evidence. Consumer interest in fat loss, longevity, and performance greatly exceeds the strength of the clinical evidence [15]. - Single-lab and small-sample reliance for some findings; certain mechanistic effects await independent replication. No community-anecdote reports are compiled in this desk's source material for MOTS-c; the cautions above are from the cited literature. ## Where it fits in metabolic research MOTS-c is the most mechanistically novel entry on this desk — a peptide encoded in an entirely different genome from every other signaling molecule studied in this context. Its AMPK activation pathway, CK2 binding target, and nuclear translocation under stress are each precisely mapped [13][17]. What it lacks is the human trial record that [Tesamorelin](/tesamorelin) has in its specific indication, or even the failed human translation that [AOD-9604](/aod-9604) provides as a clear boundary condition. MOTS-c is genuinely earlier-stage, its mechanistic promise is real, and its human evidence is currently an observational biomarker cohort study [14] — not an efficacy trial. See how it lines up on the [comparison page](/compare). ![MOTS-c mitochondrial peptide and AMPK skeletal-muscle signaling pathway in cold glacier tones](/images/mots-c.webp) --- A precision literature digest — what the studies actually show, in the species they actually studied.